UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 1, 2018

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES X

NO ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES X

NO ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___ Emerging growth company ___

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ____

NO X

At August 6, 2018, 5,862,109,503 shares of the issuer s voting common stock were outstanding.

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and six months ended July 1, 2018 and July 2, 2017

Condensed Consolidated Statements of Comprehensive Income for the three and six months ended July 1, 2018 and July 2, 2017

Condensed Consolidated Balance Sheets as of July 1, 2018 and December 31, 2017

Condensed Consolidated Statements of Cash Flows for the six months ended July 1, 2018 and July 2, 2017

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

52

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

53

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

113

Item 4.

Controls and Procedures

113

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

114

Item 1A.

Risk Factors

114

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

115

Item 3.

Defaults Upon Senior Securities

115

Item 4.

Mine Safety Disclosures

115

Item 5.

Other Information

115

Item 6.

Exhibits

116

Signature

117

GLOSSARY OF DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:

2017 Financial Report

Financial Report for the fiscal year ended December 31, 2017, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2017

2017 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2017

ACA (Also referred to as U.S. Healthcare Legislation)

U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act

ACIP

Advisory Committee on Immunization Practices

ALK

anaplastic lymphoma kinase

Alliance revenues

Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

Allogene

Allogene Therapeutics, Inc.

AMPA

-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

Anacor

Anacor Pharmaceuticals, Inc.

AOCI

Accumulated Other Comprehensive Income

Astellas

Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

ASU

Accounting Standards Update

ATM-AVI

aztreonam-avibactam

Avillion

Avillion LLP

Biogen

Biogen Inc.

BMS

Bristol-Myers Squibb Company

BRCA

BReast CAncer susceptibility gene

CAR T

chimeric antigen receptor T cell

CDC

U.S. Centers for Disease Control and Prevention

Cellectis

Cellectis S.A.

CIAS

cognitive impairment associated with schizophrenia

Citibank

Citibank, N.A.

CML

chronic myelogenous leukemia

Developed Markets

U.S., Western Europe, Japan, Canada, Australia, South Korea, Scandinavian countries, Finland and New Zealand

EEA

European Economic Area

EH

Essential Health

EMA

European Medicines Agency

Emerging Markets

Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey

EPS

earnings per share

EU

European Union

Exchange Act

Securities Exchange Act of 1934, as amended

FASB

Financial Accounting Standards Board

FDA

U.S. Food and Drug Administration

GAAP

Generally Accepted Accounting Principles

GIST

gastrointestinal stromal tumors

GPD

Global Product Development

HER2-

human epidermal growth factor receptor 2-negative

hGH-CTP

human growth hormone

HIS

Hospira Infusion Systems

Hisun Pfizer

Hisun Pfizer Pharmaceuticals Company Limited

Hospira

Hospira, Inc.

HR+

hormone receptor-positive

ICU Medical

ICU Medical, Inc.

IH

Innovative Health

IPR&D

in-process research and development

IRS

U.S. Internal Revenue Service

IV

intravenous

Janssen

Janssen Biotech Inc.

J&J

Johnson & Johnson Corp.

King

King Pharmaceuticals, Inc.

LDL

low density lipoprotein

LEP

Legacy Established Products

LIBOR

London Interbank Offered Rate

Lilly

Eli Lilly & Company

LOE

loss of exclusivity

MCC

Merkel Cell Carcinoma

MCO

Managed Care Organization

MD&A

Management s Discussion and Analysis of Financial Condition and Results of Operations

Medivation

Medivation, Inc.

Merck

Merck & Co., Inc.

Meridian

Meridian Medical Technologies, Inc.

Moody s

Moody s Investors Service

NDA

new drug application

NovaQuest

NovaQuest Co-Investment Fund V, L.P.

NSCLC

non-small cell lung cancer

NYSE

New York Stock Exchange

OPKO

OPKO Health, Inc.

OTC

over-the-counter

PARP

poly ADP ribose polymerase

PBM

Pharmacy Benefit Manager

Pharmacia

Pharmacia Corporation

PP&E

Property, plant & equipment

Quarterly Report on Form 10-Q

Quarterly Report on Form 10-Q for the quarterly period ended July 1, 2018

RCC

renal cell carcinoma

R&D

research and development

RPI

RPI Finance Trust

Sandoz

Sandoz, Inc., a division of Novartis AG

SEC

U.S. Securities and Exchange Commission

Servier

Les Laboratoires Servier SAS

SFJ

SFJ Pharmaceuticals Group

Shire

Shire International GmbH

SIP

Sterile Injectable Pharmaceuticals

S&P

Standard and Poor s

StratCO

Strategy and Commercial Operations

Tax Cuts and Jobs Act or TCJA

Legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017

Teuto

Laborat rio Teuto Brasileiro S.A.

U.K.

United Kingdom

U.S.

United States

VAI

Voluntary Action Indicated

ViiV

ViiV Healthcare Limited

WRD

Worldwide Research and Development

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

July 1,

2018

July 2,

2017

July 1,

2018

July 2,

2017

Revenues

13,466

12,896

26,373

25,675

Costs and expenses:

Cost of sales(a)

2,916

2,660

5,479

5,128

Selling, informational and administrative expenses(a)

3,542

3,430

6,954

6,745

Research and development expenses(a)

1,797

1,787

3,540

3,502

Amortization of intangible assets

1,191

1,208

2,387

2,394

Restructuring charges and certain acquisition-related costs

44

70

87

153

Other (income)/deductions net

(551

(75

(728

(14

Income from continuing operations before provision for taxes on income

4,527

3,815

8,654

7,767

Provision for taxes on income

648

739

1,204

1,560

Income from continuing operations

3,879

3,077

7,450

6,207

Discontinued operations net of tax

(1

Net income before allocation to noncontrolling interests

3,879

3,078

7,449

6,208

Less: Net income attributable to noncontrolling interests

16

14

Net income attributable to Pfizer Inc.

3,872

3,073

7,432

6,194

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.66

0.52

1.26

1.04

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.66

0.52

1.26

1.04

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.65

0.51

1.24

1.02

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.65

0.51

1.24

1.02

Weighted-average shares basic

5,866

5,958

5,911

5,982

Weighted-average shares diluted

5,952

6,037

6,004

6,065

Cash dividends paid per common share

0.34

0.32

0.68

0.64

(a)

Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS OF DOLLARS)

July 1,

2018

July 2,

2017

July 1,

2018

July 2,

2017

Net income before allocation to noncontrolling interests

3,879

3,078

7,449

6,208

Foreign currency translation adjustments, net

(699

247

59

474

Reclassification adjustments

(35

111

(20

112

(734

358

39

586

Unrealized holding gains/(losses) on derivative financial instruments, net

127

(90

13

(99

Reclassification adjustments for (gains)/losses included in net income(a)

310

(208

354

(449

437

(297

367

(548

Unrealized holding gains/(losses) on available-for-sale securities, net

(374

164

(214

314

Reclassification adjustments for (gains)/losses included in net income(a)

143

(40

(31

97

Reclassification adjustments for unrealized gains included in Retained earnings(b)

(462

(231

124

(707

412

Benefit plans: actuarial gains/(losses), net

(57

61

106

62

Reclassification adjustments related to amortization

61

145

123

308

Reclassification adjustments related to settlements, net

30

(1

67

51

Other

107

(80

21

(35

141

124

316

385

Benefit plans: prior service costs and other, net

(2

(2

Reclassification adjustments related to amortization

(46

(46

(92

(91

Reclassification adjustments related to curtailments, net

(7

(4

(13

(11

Other

(1

(53

(52

(104

(104

Other comprehensive income/(loss), before tax

(440

258

(88

732

Tax provision/(benefit) on other comprehensive income/(loss)

173

(163

605

(138

Other comprehensive income/(loss) before allocation to noncontrolling interests

(613

421

(693

870

Comprehensive income before allocation to noncontrolling interests

3,266

3,499

6,755

7,078

Less: Comprehensive income/(loss) attributable to noncontrolling interests

(4

13

29

Comprehensive income attributable to Pfizer Inc.

3,270

3,486

6,750

7,049

(a)

Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see Note 7F. Financial Instruments: Derivative Financial Instruments and Hedging Activities.

(b)

For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

July 1,

2018

December 31,

2017

(Unaudited)

Assets

Cash and cash equivalents

2,704

1,342

Short-term investments

10,727

18,650

Trade accounts receivable, less allowance for doubtful accounts: 2018 $578; 2017 $584

9,873

8,221

Inventories

8,074

7,578

Current tax assets

3,582

3,050

Other current assets

2,343

2,301

Total current assets

37,303

41,141

Long-term investments

6,595

7,015

Property, plant and equipment, less accumulated depreciation: 2018 $16,844; 2017 $16,172

13,919

13,865

Identifiable intangible assets, less accumulated amortization

46,584

48,741

Goodwill

55,836

55,952

Noncurrent deferred tax assets and other noncurrent tax assets

1,848

1,855

Other noncurrent assets

2,896

3,227

Total assets

164,980

171,797

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2018 $4,262; 2017 $3,546

11,583

9,953

Trade accounts payable

4,196

4,656

Dividends payable

1,980

2,029

Income taxes payable

2,481

477

Accrued compensation and related items

1,791

2,196

Other current liabilities

10,125

11,115

Total current liabilities

32,156

30,427

Long-term debt

28,935

33,538

Pension benefit obligations, net

5,006

5,926

Postretirement benefit obligations, net

1,473

1,504

Noncurrent deferred tax liabilities

5,743

3,900

Other taxes payable

15,597

18,697

Other noncurrent liabilities

5,947

6,149

Total liabilities

94,856

100,141

Commitments and Contingencies

Preferred stock

20

21

Common stock

465

464

Additional paid-in capital

84,898

84,278

Treasury stock

(95,463

(89,425

Retained earnings

89,860

85,291

Accumulated other comprehensive loss

(10,003

(9,321

Total Pfizer Inc. shareholders equity

69,778

71,308

Equity attributable to noncontrolling interests

346

348

Total equity

70,124

71,656

Total liabilities and equity

164,980

171,797

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months Ended

(MILLIONS OF DOLLARS)

July 1,

2018

July 2,

2017

Operating Activities

Net income before allocation to noncontrolling interests

7,449

6,208

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:

Depreciation and amortization

3,129

3,129

Asset write-offs and impairments

41

97

Adjustments to loss on sale of HIS net assets

64

TCJA impact(a)

(68

Deferred taxes from continuing operations

(500

320

Share-based compensation expense

379

388

Benefit plan contributions in excess of expense

(826

(1,079

Other adjustments, net

(523

(458

Other changes in assets and liabilities, net of acquisitions and divestitures

(3,250

(3,844

Net cash provided by operating activities

5,830

4,824

Investing Activities

Purchases of property, plant and equipment

(810

(806

Purchases of short-term investments

(3,122

(2,394

Proceeds from redemptions/sales of short-term investments

10,497

3,517

Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less

1,231

3,424

Purchases of long-term investments

(1,070

(1,663

Proceeds from redemptions/sales of long-term investments

1,361

1,538

Acquisitions of businesses, net of cash acquired

(1,000

Acquisitions of intangible assets

(32

(41

Other investing activities, net

138

455

Net cash provided by investing activities

8,193

3,030

Financing Activities

Proceeds from short-term borrowings

1,746

4,799

Principal payments on short-term borrowings

(2,921

(5,088

Net proceeds from short-term borrowings with original maturities of three months or less

2,092

265

Proceeds from issuance of long-term debt

5,273

Principal payments on long-term debt

(3,104

(4,473

Purchases of common stock

(6,063

(5,000

Cash dividends paid

(4,021

(3,855

Proceeds from exercise of stock options

474

411

Other financing activities, net

(831

(228

Net cash used in financing activities

(12,628

(7,896

Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents

(15

37

Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents

1,381

(5

Cash and cash equivalents and restricted cash and cash equivalents, beginning

1,431

2,666

Cash and cash equivalents and restricted cash and cash equivalents, end

2,811

2,661

Supplemental Cash Flow Information

Non-cash transactions:

Receipt of ICU Medical common stock(b)

428

Promissory note from ICU Medical(b)

75

Equity investment in Allogene received in exchange for Pfizer's allogeneic CAR T developmental program assets(b)

92

Cash paid (received) during the period for:

Income taxes

1,197

1,121

Interest

724

881

Interest rate hedges

(71

(226

(a)

As a result of the enactment of the TCJA in December 2017, Pfizer s 2018 Provision for taxes on income was favorably impacted by approximately $68 million, primarily related to certain tax initiatives associated with the lower U.S. tax rate as a result of the TCJA.

(b)

For additional information, see Note 2B. Acquisition, Divestitures, Licensing Arrangements, Collaborative Arrangements and Privately Held Investment: Divestitures.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies